Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, is offering a new suite of ...

Pfizer reckons it will make a whopping $22 ... run out of money and had stopped accepting new doses as it needs a cash injection of $5.2 billion to keep operating. "Pfizer…has made more than ...

Pfizer’s once-weekly antibody injection for haemophilia A and B, marstacimab, could be on track for regulatory approvals based on solid results in a phase 3 trial reported over the weekend ...

Depo-Provera has been linked to brain tumors, neurological damage, and vision loss. Lawsuits claim Pfizer failed to warn users of these risks.

IXIFI is a biosimilar to Remicade (infliximab). It was approved by Health Canada in December 2021 for all eligible indications of the reference product.

It’s only February, but my pick for the Worst Biopharma CEO of 2025 has already been decided: Albert Bourla of Pfizer. Pfizer’s decision to hire Patrizia Cavazzoni, a former top drug ...

Shares of Pfizer (NYSE:PFE) have delivered negative returns since I started covering the stock and the last four months have not been great either as it is down another 12% since my previous ...